Author
Listed:
- Makoto Nakashima
(St. Marianna University School of Medicine)
- Kaho Nagai
(University of Tokyo)
- Naoki Takao
(St. Marianna University School of Medicine)
- Natsumi Araya
(St. Marianna University School of Medicine)
- Yuuta Kuze
(The University of Tokyo)
- Jun Mizuike
(University of Tokyo)
- Shu Tosaka
(University of Tokyo
University of Tokyo)
- Satoko Aratani
(St. Marianna University School of Medicine
LSI Medience Co)
- Naoko Yagishita
(St. Marianna University School of Medicine)
- Erika Horibe
(St. Marianna University School of Medicine)
- Toshiki Watanabe
(St. Marianna University School of Medicine)
- Tomoo Sato
(St. Marianna University School of Medicine
St. Marianna University School of Medicine)
- Yasuhito Nannya
(the University of Tokyo
the University of Tokyo)
- Yutaka Suzuki
(The University of Tokyo)
- Kaoru Uchimaru
(University of Tokyo)
- Makoto Yamagishi
(University of Tokyo
University of Tokyo)
- Yoshihisa Yamano
(St. Marianna University School of Medicine
St. Marianna University School of Medicine)
Abstract
Human T-cell leukemia virus type 1 (HTLV-1)-associated myelopathy (HAM) is a debilitating neuroinflammatory disease with no available effective treatments. A hallmark of HAM is the transformation of HTLV-1-infected cells into T helper type 1 (Th1)-like cells, characterized by excessive interferon (IFN)-γ production that drives chronic inflammation. However, the molecular mechanisms fuel this aberrant Th1-like transformation and sustained inflammation remain poorly understood. We hypothesized that HAM-characteristic chromatin remodeling plays a pivotal role in the overexpression of key genes driving inflammatory pathogenesis. Using transcriptomic analysis, chromatin accessibility profiling, and biomarker evaluations across HTLV-1-related diseases, we identify MAP3K8 as a key gene that defines the unique inflammatory profile of HAM. MAP3K8 overexpression promotes Th1-like differentiation and constitutively activates the MEK-ERK signaling pathway. Furthermore, we elucidate the mechanism by which HTLV-1 Tax, Fosl2, and c-Jun collaboratively induce HAM-characteristic chromatin remodeling at the enhancer region of the MAP3K8 locus. Crucially, we demonstrate that mitogen-activated protein kinase kinase (MEK) inhibitors effectively suppress the MAP3K8-MEK signaling cascade and significantly mitigated inflammatory pathogenesis in an ex vivo culture assay. Our findings provide critical insights into the virus-host interactions underpinning HAM and propose the MAP3K8-MEK-ERK axis as a promising therapeutic target for this challenging condition.
Suggested Citation
Makoto Nakashima & Kaho Nagai & Naoki Takao & Natsumi Araya & Yuuta Kuze & Jun Mizuike & Shu Tosaka & Satoko Aratani & Naoko Yagishita & Erika Horibe & Toshiki Watanabe & Tomoo Sato & Yasuhito Nannya , 2025.
"Chromatin remodeling enhances MAP3K8 expression in HAM: a key pathogenesis for therapeutic intervention,"
Nature Communications, Nature, vol. 16(1), pages 1-17, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-64836-7
DOI: 10.1038/s41467-025-64836-7
Download full text from publisher
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-64836-7. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.